Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictors

被引:40
|
作者
Paul, Subroto [1 ]
Mirza, Farooq [1 ]
Port, Jeffrey L. [1 ]
Lee, Paul C. [1 ]
Stiles, Brendon M. [1 ]
Kansler, Amanda L. [1 ]
Altorki, Nasser K. [1 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Thorac Surg, Dept Cardiothorac Surg, New York, NY 10065 USA
来源
关键词
RANDOMIZED CONTROLLED-TRIAL; COMPARING PERIOPERATIVE CHEMOTHERAPY; HIGH-DOSE RADIATION; PREOPERATIVE CHEMOTHERAPY; SURGICAL RESECTION; NEOADJUVANT THERAPY; PHASE-III; FOLLOW-UP; NODES N2; SURGERY;
D O I
10.1016/j.jtcvs.2010.07.092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In clinical stage IIIA non-small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. Methods: We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010. Results: One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69-136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P = .002), extent of resection (hazard ratio, 2.01; P = .026), and presence of residual pN2 (hazard ratio, 1.60; P = .047). Conclusions: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy. (J Thorac Cardiovasc Surg 2011;141:48-58)
引用
收藏
页码:48 / 58
页数:11
相关论文
共 50 条
  • [1] Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer
    Kamel, Mohamed K.
    Rahouma, Mohamed
    Ghaly, Galal
    Nasar, Abu
    Port, Jeffrey L.
    Stiles, Brendon M.
    Nguyen, Andrew B.
    Altorki, Nasser K.
    Lee, Paul C.
    ANNALS OF THORACIC SURGERY, 2017, 103 (01): : 281 - 286
  • [2] Resection of Persistent Stage IIIA-N2 Non-small Cell Lung Cancer After Induction Therapy
    Andrews, Weston G.
    Louie, Brian E.
    Bograd, Adam J.
    ANNALS OF THORACIC SURGERY, 2022, 114 (06): : 2392 - 2393
  • [3] Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer
    Vest, Michael T.
    Tanoue, Lynn
    Soulos, Pamela R.
    Kim, Anthony W.
    Detterbeck, Frank
    Morgensztern, Daniel
    Gross, Cary P.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) : 188 - 195
  • [4] Adjuvant Chemotherapy Improves Survival in pN-positive Clinical Stage IIIA Non-Small Cell Lung Cancer After Neoadjuvant Therapy and Resection
    Atay, Scott M.
    Amini, Maziar
    Ding, Li
    David, Elizabeth A.
    Mcfadden, P. Michael
    Wightman, Sean C.
    Kim, Anthony W.
    ANNALS OF THORACIC SURGERY, 2021, 112 (01): : 197 - 205
  • [5] Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy
    Hyebin Lee
    Yong Chan Ahn
    Hongryull Pyo
    BoKyong Kim
    Dongryul Oh
    Heerim Nam
    Eunju Lee
    Jong-Mu Sun
    Jin Seok Ahn
    Myung-Ju Ahn
    Keunchil Park
    Yong Soo Choi
    Jhingook Kim
    Jae Ill Zo
    Young Mog Shim
    Annals of Surgical Oncology, 2014, 21 : 2083 - 2090
  • [6] Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy
    Lee, Hyebin
    Ahn, Yong Chan
    Pyo, Hongryull
    Kim, BoKyong
    Oh, Dongryul
    Nam, Heerim
    Lee, Eunju
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Choi, Yong Soo
    Kim, Jhingook
    Zo, Jae Ill
    Shim, Young Mog
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (06) : 2083 - 2090
  • [7] Pulmonary Resection of Non-Small Cell Lung Cancer: Is Survival in the Elderly Not Affected by Tumor Stage after Complete Resection?
    Boeluekbas, S.
    Beqiri, S.
    Bergmann, T.
    Trainer, S.
    Fisseler-Eckhoff, A.
    Schirren, J.
    THORACIC AND CARDIOVASCULAR SURGEON, 2008, 56 (08): : 476 - 481
  • [8] Markers of tumor invasion as predictors of survival after resection of non-small cell lung cancer in stage I
    Klein, J
    Kral, V
    Tichy, T
    Neoral, C
    Bohanes, T
    Drac, P
    Skarda, J
    Rihakova, P
    Grygarkova, I
    Kolar, Z
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 419 - 419
  • [9] Timing of Surgery After Neoadjuvant Chemoradiation in Clinical Stage IIIA Non-Small Cell Lung Cancer With Mediastinal Nodal Involvement
    Gao, S.
    Corso, C. D.
    Wang, E. H.
    Blasberg, J.
    Boffa, D.
    Detterbeck, F. C.
    Kim, A. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E470 - E470
  • [10] Role of Induction Therapy Surgical Resection of Non-Small Cell Lung Cancer After Induction Therapy
    Ripley, R. Taylor
    Rusch, Valerie W.
    THORACIC SURGERY CLINICS, 2013, 23 (03) : 273 - +